Digestive Disease Interventions 2020; 04(03): 248-259
DOI: 10.1055/s-0040-1716738
Review Article

Epidemiology, Prevention, Diagnosis, and Management of Venous Thromboembolism in Gastrointestinal Cancers

William J. Chapin
1   Division of Hematology/Oncology, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
,
Preeti Sudheendra
2   Division of Hematology and Oncology, Cooper University Hospital, Camden, New Jersey
,
3   Division of Interventional Radiology, Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
,
3   Division of Interventional Radiology, Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
› Institutsangaben

Abstract

Venous thromboembolism (VTE) is a leading cause of cardiovascular death and is associated with significant morbidity. Patients with cancer, and gastrointestinal (GI) malignancies in particular, are at increased risk of VTE, increased risk of bleeding with VTE treatment, and increased risk of recurrent VTE compared with the general population. VTE has been shown to be a leading cause of death among patients with cancer. This review will discuss special considerations in the prevention, diagnosis, and management of VTE in patients with GI malignancies. Given the increased risk of VTE observed in ambulatory patients with GI malignancies, multiple trials have examined and demonstrated the efficacy of prophylactic anticoagulation in high-risk patients with cancer undergoing chemotherapy, particularly in patients with gastric and pancreatic cancers. Patients with GI malignancies have also played a central role in discussions of the risks and benefits of the use of direct oral anticoagulants in patients with cancers, with first-line anticoagulation options expanding to include low-molecular-weight heparin, rivaroxaban, edoxaban, and apixaban. However, there continue to be concerns regarding an increased risk of bleeding with edoxaban and rivaroxaban in patients with GI malignancies. In addition to anticoagulation, individualized risk and benefit analysis should be undertaken for interventions including inferior vena cava (IVC) filter placement and catheter-directed thrombolysis in the setting of increased risk of bleeding and recurrent VTE for patients with GI malignancies. Several unique scenarios that may be seen with GI malignancies, including incidental VTE, splanchnic vein thrombosis, IVC thrombosis, and iliac vein compression, require individualized decision making.



Publikationsverlauf

Eingereicht: 02. April 2020

Angenommen: 23. Juli 2020

Artikel online veröffentlicht:
22. September 2020

© 2020. Thieme. All rights reserved.

Thieme Medical Publishers
333 Seventh Avenue, New York, NY 10001, USA.

 
  • References

  • 1 Goldhaber SZ, Bounameaux H. Pulmonary embolism and deep vein thrombosis. Lancet 2012; 379 (9828): 1835-1846
  • 2 Beckman MG, Hooper WC, Critchley SE, Ortel TL. Venous thromboembolism: a public health concern. Am J Prev Med 2010; 38 (4, Suppl): S495-S501
  • 3 Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. Blood 2013; 122 (10) 1712-1723
  • 4 Cohen AT, Katholing A, Rietbrock S, Bamber L, Martinez C. Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study. Thromb Haemost 2017; 117 (01) 57-65
  • 5 Khalil J, Bensaid B, Elkacemi H. et al. Venous thromboembolism in cancer patients: an underestimated major health problem. World J Surg Oncol 2015; 13: 204
  • 6 Ay C, Pabinger I, Cohen AT. Cancer-associated venous thromboembolism: burden, mechanisms, and management. Thromb Haemost 2017; 117 (02) 219-230
  • 7 Larsen AC, Dabrowski T, Frøkjær JB. et al. Prevalence of venous thromboembolism at diagnosis of upper gastrointestinal cancer. Br J Surg 2014; 101 (03) 246-253
  • 8 Cronin-Fenton DP, Søndergaard F, Pedersen LA. et al. Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997-2006. Br J Cancer 2010; 103 (07) 947-953
  • 9 Walker AJ, Card TR, West J, Crooks C, Grainge MJ. Incidence of venous thromboembolism in patients with cancer - a cohort study using linked United Kingdom databases. Eur J Cancer 2013; 49 (06) 1404-1413
  • 10 Prandoni P, Lensing AWA, Piccioli A. et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100 (10) 3484-3488
  • 11 Farge D, Trujillo-Santos J, Debourdeau P. et al. RIETE Investigators. Fatal events in cancer patients receiving anticoagulant therapy for venous thromboembolism. Medicine (Baltimore) 2015; 94 (32) e1235
  • 12 Monreal M, Falgá C, Valdés M. et al. Riete Investigators. Fatal pulmonary embolism and fatal bleeding in cancer patients with venous thromboembolism: findings from the RIETE registry. J Thromb Haemost 2006; 4 (09) 1950-1956
  • 13 Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JG, Büller HR. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 2000; 18 (17) 3078-3083
  • 14 Zakai NA, Walker RF, MacLehose RF, Adam TJ, Alonso A, Lutsey PL. Impact of anticoagulant choice on hospitalized bleeding risk when treating cancer-associated venous thromboembolism. J Thromb Haemost 2018; 16 (12) 2403-2412
  • 15 Raskob GE, van Es N, Verhamme P. et al. Hokusai VTE Cancer Investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018; 378 (07) 615-624
  • 16 Young AM, Marshall A, Thirlwall J. et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018; 36 (20) 2017-2023
  • 17 Lee JH, Oh YM, Lee SD, Lee JS. Rivaroxaban versus low-molecular-weight heparin for venous thromboembolism in gastrointestinal and pancreatobiliary cancer. J Korean Med Sci 2019; 34 (21) e160
  • 18 Recio-Boiles A, Veeravelli S, Vondrak J. et al. Evaluation of the safety and effectiveness of direct oral anticoagulants and low molecular weight heparin in gastrointestinal cancer-associated venous thromboembolism. World J Gastrointest Oncol 2019; 11 (10) 866-876
  • 19 Kim JH, Seo S, Kim K-P. et al. Rivaroxaban versus low-molecular-weight heparin for venous thromboembolism in advanced upper gastrointestinal tract and hepatopancreatobiliary cancer. In Vivo 2020; 34 (02) 829-837
  • 20 Douketis JD, Crowther MA, Foster GA, Ginsberg JS. Does the location of thrombosis determine the risk of disease recurrence in patients with proximal deep vein thrombosis?. Am J Med 2001; 110 (07) 515-519
  • 21 Sørensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343 (25) 1846-1850
  • 22 Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007; 5 (03) 632-634
  • 23 Font C, Carmona-Bayonas A, Beato C. et al. Asociación para la Investigación de la Enfermedad Tromboembólica de la región de Murcia. Clinical features and short-term outcomes of cancer patients with suspected and unsuspected pulmonary embolism: the EPIPHANY study. Eur Respir J 2017; 49 (01) 1600282
  • 24 Agnelli G, Gussoni G, Bianchini C. et al. PROTECHT Investigators. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol 2009; 10 (10) 943-949
  • 25 Agnelli G, George DJ, Kakkar AK. et al. SAVE-ONCO Investigators. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med 2012; 366 (07) 601-609
  • 26 Maraveyas A, Waters J, Roy R. et al. Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. Eur J Cancer 2012; 48 (09) 1283-1292
  • 27 Pelzer U, Opitz B, Deutschinoff G. et al. Efficacy of prophylactic low-molecular weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO-004 trial. J Clin Oncol 2015; 33 (18) 2028-2034
  • 28 Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111 (10) 4902-4907
  • 29 Ay C, Dunkler D, Marosi C. et al. Prediction of venous thromboembolism in cancer patients. Blood 2010; 116 (24) 5377-5382
  • 30 Carrier M, Abou-Nassar K, Mallick R. et al. AVERT Investigators. Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med 2019; 380 (08) 711-719
  • 31 Khorana AA, Soff GA, Kakkar AK. et al. CASSINI Investigators. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med 2019; 380 (08) 720-728
  • 32 Key NS, Khorana AA, Kuderer NM. et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol 2020; 38 (05) 496-520
  • 33 Park DY, Khorana AA. Risks and benefits of anticoagulation in cancer and noncancer patients. Semin Thromb Hemost 2019; 45 (06) 629-637
  • 34 Kraft C, Hecking C, Schwonberg J, Schindewolf M, Lindhoff-Last E, Linnemann B. Patients with inferior vena cava thrombosis frequently present with lower back pain and bilateral lower-extremity deep vein thrombosis. Vasa 2013; 42 (04) 275-283
  • 35 Kumar S, Sarr MG, Kamath PS. Mesenteric venous thrombosis. N Engl J Med 2001; 345 (23) 1683-1688
  • 36 Moore RA, Adel N, Riedel E. et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J Clin Oncol 2011; 29 (25) 3466-3473
  • 37 Singh R, Sousou T, Mohile S, Khorana AA. High rates of symptomatic and incidental thromboembolic events in gastrointestinal cancer patients. J Thromb Haemost 2010; 8 (08) 1879-1881
  • 38 Imberti D, Agnelli G, Ageno W. et al. MASTER Investigators. Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the MASTER Registry. Haematologica 2008; 93 (02) 273-278
  • 39 Wells PS, Ihaddadene R, Reilly A, Forgie MA. Diagnosis of venous thromboembolism: 20 years of progress. Ann Intern Med 2018; 168 (02) 131-140
  • 40 Le Gal G, Righini M, Roy P-M. et al. Prediction of pulmonary embolism in the emergency department: the revised Geneva score. Ann Intern Med 2006; 144 (03) 165-171
  • 41 Wells PS, Hirsh J, Anderson DR. et al. Accuracy of clinical assessment of deep-vein thrombosis. Lancet 1995; 345 (8961): 1326-1330
  • 42 van Es N, van der Hulle T, van Es J. et al. PO-07 - Excluding pulmonary embolism in cancer patients using the Wells rule and age-adjusted D-dimer testing: an individual patient data meta-analysis. Thromb Res 2016; 140 (Suppl. 01) S179
  • 43 Wilts IT, Le Gal G, Den Exter PL. et al. Performance of the age-adjusted cut-off for D-dimer in patients with cancer and suspected pulmonary embolism. Thromb Res 2017; 152: 49-51
  • 44 Johnson SA, Stevens SM, Woller SC. et al. Risk of deep vein thrombosis following a single negative whole-leg compression ultrasound: a systematic review and meta-analysis. JAMA 2010; 303 (05) 438-445
  • 45 Bhatt M, Braun C, Patel P. et al. Diagnosis of deep vein thrombosis of the lower extremity: a systematic review and meta-analysis of test accuracy. Blood Adv 2020; 4 (07) 1250-1264
  • 46 Hayashino Y, Goto M, Noguchi Y, Fukui T. Ventilation-perfusion scanning and helical CT in suspected pulmonary embolism: meta-analysis of diagnostic performance. Radiology 2005; 234 (03) 740-748
  • 47 van der Hulle T, van Es N, den Exter PL. et al. Is a normal computed tomography pulmonary angiography safe to rule out acute pulmonary embolism in patients with a likely clinical probability? A patient-level meta-analysis. Thromb Haemost 2017; 117 (08) 1622-1629
  • 48 Vedantham S, Sista AK, Klein SJ. et al. Society of Interventional Radiology and Cardiovascular and Interventional Radiological Society of Europe Standards of Practice Committees. Quality improvement guidelines for the treatment of lower-extremity deep vein thrombosis with use of endovascular thrombus removal. J Vasc Interv Radiol 2014; 25 (09) 1317-1325
  • 49 Kearon C, Akl EA, Ornelas J. et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 2016; 149 (02) 315-352
  • 50 Kearon C. Natural history of venous thromboembolism. Circulation 2003; 107 (23) (Suppl. 01) I22-I30
  • 51 Kahale LA, Hakoum MB, Tsolakian IG. et al. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer. Cochrane Database Syst Rev 2018; 6: CD006650
  • 52 Posch F, Königsbrügge O, Zielinski C, Pabinger I, Ay C. Treatment of venous thromboembolism in patients with cancer: a network meta-analysis comparing efficacy and safety of anticoagulants. Thromb Res 2015; 136 (03) 582-589
  • 53 Agnelli G, Becattini C, Meyer G. et al. Caravaggio Investigators. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 2020; 382 (17) 1599-1607
  • 54 National Comprehensive Cancer Network. Cancer-associated venous thromboembolic disease (Version 1.2020). Available at: https://www.nccn.org/professionals/physician_gls/pdf/vte.pdf . Accessed May 10, 2020
  • 55 Menapace LA, Peterson DR, Berry A, Sousou T, Khorana AA. Symptomatic and incidental thromboembolism are both associated with mortality in pancreatic cancer. Thromb Haemost 2011; 106 (02) 371-378
  • 56 den Exter PL, Hooijer J, Dekkers OM, Huisman MV. Risk of recurrent venous thromboembolism and mortality in patients with cancer incidentally diagnosed with pulmonary embolism: a comparison with symptomatic patients. J Clin Oncol 2011; 29 (17) 2405-2409
  • 57 Lyman GH, Khorana AA, Kuderer NM. et al. American Society of Clinical Oncology Clinical Practice. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013; 31 (17) 2189-2204
  • 58 Decousus H, Leizorovicz A, Parent F. et al. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med 1998; 338 (07) 409-415
  • 59 Muriel A, Jiménez D, Aujesky D. et al. RIETE Investigators. Survival effects of inferior vena cava filter in patients with acute symptomatic venous thromboembolism and a significant bleeding risk. J Am Coll Cardiol 2014; 63 (16) 1675-1683
  • 60 Brunson A, Ho G, White R, Wun T. Inferior vena cava filters in patients with cancer and venous thromboembolism (VTE) does not improve clinical outcomes: a population-based study. Thromb Res 2017; 153: 57-64
  • 61 Grewal S, Chamarthy MR, Kalva SP. Complications of inferior vena cava filters. Cardiovasc Diagn Ther 2016; 6 (06) 632-641
  • 62 Martin MJ, Blair KS, Curry TK, Singh N. Vena cava filters: current concepts and controversies for the surgeon. Curr Probl Surg 2010; 47 (07) 524-618
  • 63 Health C for D and R. Safety Communications - Removing Retrievable Inferior Vena Cava Filters. FDA safety communication. Available at: https://wayback.archive-it.org/7993/20170111070016/http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm396377.htm . Accessed April 30, 2020
  • 64 Kahn SR, Shbaklo H, Lamping DL. et al. Determinants of health-related quality of life during the 2 years following deep vein thrombosis. J Thromb Haemost 2008; 6 (07) 1105-1112
  • 65 Vedantham S, Goldhaber SZ, Julian JA. et al. ATTRACT Trial Investigators. Pharmacomechanical catheter-directed thrombolysis for deep-vein thrombosis. N Engl J Med 2017; 377 (23) 2240-2252
  • 66 Kahn SR, Julian JA, Kearon C. et al. ATTRACT Trial Investigators. Quality of life after pharmacomechanical catheter-directed thrombolysis for proximal deep venous thrombosis. J Vasc Surg Venous Lymphat Disord 2020; 8 (01) 8.e18-23.e18
  • 67 Comerota AJ, Kearon C, Gu C-S. et al. ATTRACT Trial Investigators. Endovascular thrombus removal for acute iliofemoral deep vein thrombosis. Circulation 2019; 139 (09) 1162-1173
  • 68 Yoon WJ, Halandras P, Aulivola B, Crisostomo P. Malignancy does not affect outcomes of pharmacomechanical thrombolysis in acute symptomatic iliofemoral deep vein thrombosis. Ann Vasc Surg 2018; 51: 234-238
  • 69 Brailovsky Y, Yeung H-M, Lakhter V, Zack CJ, Zhao H, Bashir R. In-hospital outcomes of catheter-directed thrombolysis versus anticoagulation in cancer patients with proximal deep venous thrombosis. J Vasc Surg Venous Lymphat Disord 2020; 8 (04) 538.e3-544.e3
  • 70 Bashir R, Zack CJ, Zhao H, Comerota AJ, Bove AA. Comparative outcomes of catheter-directed thrombolysis plus anticoagulation vs anticoagulation alone to treat lower-extremity proximal deep vein thrombosis. JAMA Intern Med 2014; 174 (09) 1494-1501
  • 71 Kim HS, Preece SR, Black JH, Pham LD, Streiff MB. Safety of catheter-directed thrombolysis for deep venous thrombosis in cancer patients. J Vasc Surg 2008; 47 (02) 388-394
  • 72 Park K-S, Kim M, Park S-H, Lee K-W. Nervous system involvement by pancreatic cancer. J Neurooncol 2003; 63 (03) 313-316
  • 73 Cascino TL, Leavengood JM, Kemeny N, Posner JB. Brain metastases from colon cancer. J Neurooncol 1983; 1 (03) 203-209
  • 74 Lin L, Zhao C-H, Ge F-J. et al. Patients with brain metastases derived from gastrointestinal cancer: clinical characteristics and prognostic factors. Clin Transl Oncol 2016; 18 (01) 93-98
  • 75 Crowner JR, Marston W. Percutaneous thrombectomy using a novel single-session device for acute ilio-caval deep vein thrombosis. J Vasc Surg Cases Innov Tech 2019; 5 (03) 302-304
  • 76 Kahn SR, Shapiro S, Wells PS. et al. SOX trial investigators. Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial. Lancet 2014; 383 (9920): 880-888
  • 77 Appelen D, van Loo E, Prins MH, Neumann MH, Kolbach DN. Compression therapy for prevention of post-thrombotic syndrome. Cochrane Database Syst Rev 2017; 9: CD004174
  • 78 Avila ML, Montoya M, Lumia C, Marson A, Brandão LR, Tomlinson G. Compression stockings to prevent post-thrombotic syndrome in adults, a Bayesian meta-analysis. Thromb Res 2019; 182: 20-26
  • 79 Peters M, Syed RK, Katz M. et al. May-Thurner syndrome: a not so uncommon cause of a common condition. Proc Bayl Univ Med Cent 2012; 25 (03) 231-233
  • 80 O'Sullivan GJ, Sheehan J, Lohan D, McCann-Brown JA. Iliofemoral venous stenting extending into the femoral region: initial clinical experience with the purpose-designed Zilver Vena stent. J Cardiovasc Surg (Torino) 2013; 54 (02) 255-261
  • 81 Titus JM, Moise MA, Bena J, Lyden SP, Clair DG. Iliofemoral stenting for venous occlusive disease. J Vasc Surg 2011; 53 (03) 706-712
  • 82 Maleux G, Vertenten B, Laenen A. et al. Palliative endovascular treatment of cancer-related iliocaval obstructive disease: technical and clinical outcomes. Acta Radiol 2016; 57 (04) 451-456
  • 83 Stein PD, Matta F, Yaekoub AY. Incidence of vena cava thrombosis in the United States. Am J Cardiol 2008; 102 (07) 927-929
  • 84 Linnemann B, Schmidt H, Schindewolf M. et al. Etiology and VTE risk factor distribution in patients with inferior vena cava thrombosis. Thromb Res 2008; 123 (01) 72-78
  • 85 Lee IJ, Chung JW, Kim H-C. et al. Extrahepatic collateral artery supply to the tumor thrombi of hepatocellular carcinoma invading inferior vena cava: the prevalence and determinant factors. J Vasc Interv Radiol 2009; 20 (01) 22-29
  • 86 Shapero KS, Jelani Q-U-A, Mena C. Endovascular treatment of inferior vena cava thrombosis in metastatic malignancy: a case report and review of literature. Vasc Endovascular Surg 2019; 53 (06) 507-511
  • 87 McAree BJ, O'Donnell ME, Fitzmaurice GJ, Reid JA, Spence RA, Lee B. Inferior vena cava thrombosis: a review of current practice. Vasc Med 2013; 18 (01) 32-43
  • 88 Wallace MJ. Transatrial stent placement for treatment of inferior vena cava obstruction secondary to extension of intracardiac tumor thrombus from hepatocellular carcinoma. J Vasc Interv Radiol 2003; 14 (10) 1339-1343
  • 89 Razavi MK, Hansch EC, Kee ST, Sze DY, Semba CP, Dake MD. Chronically occluded inferior venae cavae: endovascular treatment. Radiology 2000; 214 (01) 133-138
  • 90 Chen Z-H, Zhang X-P, Wang K. et al. Liver resection versus transcatheter arterial chemoembolization for the treatment of patients with hepatocellular carcinoma and hepatic vein or inferior vena cava tumor thrombus: a propensity score matching analysis. Hepatol Res 2019; 49 (04) 441-452
  • 91 Rim CH, Kim CY, Yang DS, Yoon WS. External beam radiation therapy to hepatocellular carcinoma involving inferior vena cava and/or right atrium: a meta-analysis and systemic review. Radiother Oncol 2018; 129 (01) 123-129
  • 92 Søgaard KK, Darvalics B, Horváth-Puhó E, Sørensen HT. Survival after splanchnic vein thrombosis: a 20-year nationwide cohort study. Thromb Res 2016; 141: 1-7
  • 93 Connolly GC, Chen R, Hyrien O. et al. Incidence, risk factors and consequences of portal vein and systemic thromboses in hepatocellular carcinoma. Thromb Res 2008; 122 (03) 299-306
  • 94 Pachón Olmos V, Garcia Adrian S, Cavanagh Podesta M. et al. Splanchnic vein thrombosis in ambulatory pancreatic cancer patients receiving chemotherapy. J Clin Oncol 2015; 33 (15_suppl): e20658
  • 95 Afzal A, Suhong L, Gage BF. et al. Splanchnic vein thrombosis predicts worse survival in patients with advanced pancreatic cancer. Thromb Res 2020; 185: 125-131
  • 96 Cabibbo G, Enea M, Attanasio M, Bruix J, Craxì A, Cammà C. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology 2010; 51 (04) 1274-1283
  • 97 Ageno W, Riva N, Schulman S. et al. Long-term clinical outcomes of splanchnic vein thrombosis: results of an international registry. JAMA Intern Med 2015; 175 (09) 1474-1480
  • 98 Riva N, Ageno W, Schulman S. et al. International Registry on Splanchnic Vein Thrombosis (IRSVT) study group. Clinical history and antithrombotic treatment of incidentally detected splanchnic vein thrombosis: a multicentre, international prospective registry. Lancet Haematol 2016; 3 (06) e267-e275
  • 99 Sharma AM, Zhu D, Henry Z. Portal vein thrombosis: When to treat and how?. Vasc Med 2016; 21 (01) 61-69
  • 100 Condat B, Pessione F, Hillaire S. et al. Current outcome of portal vein thrombosis in adults: risk and benefit of anticoagulant therapy. Gastroenterology 2001; 120 (02) 490-497
  • 101 Thatipelli MR, McBane RD, Hodge DO, Wysokinski WE. Survival and recurrence in patients with splanchnic vein thromboses. Clin Gastroenterol Hepatol 2010; 8 (02) 200-205
  • 102 Sherman CB, Behr S, Dodge JL, Roberts JP, Yao FY, Mehta N. Distinguishing tumor from bland portal vein thrombus in liver transplant candidates with hepatocellular carcinoma: the A-VENA criteria. Liver Transpl 2019; 25 (02) 207-216
  • 103 Mier-Hicks A, Raj M, Do RK. et al. Incidence, management, and implications of visceral thrombosis in pancreatic ductal adenocarcinoma. Clin Colorectal Cancer 2018; 17 (02) 121-128